Health Economics›Chronic lymphocytic leukemia›First-line therapy

First-line therapy

Chronic lymphocytic leukemia · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Cyclophosphamide and Fludarabine (FC) Variant #15	—	R 192 642	—	31.6 mo	—	—	—	1
Fludarabine and Rituximab (FR) Variant #06	—	R 117 749	28d	—	—	—	—	—
Idelalisib and Rituximab Variant #02 Partial	—	R 74 707	28d	~12.6 mo	—	~14	~R 1 045 903 PFS proxy · indirect	2
Cladribine and Prednisone Variant #01	—	R 55 441	28d	—	—	—	—	—
R-FCM Variant #04	—	R 46 093	42d	—	—	—	—	—
CMC Variant #01	—	R 23 596	28d	—	—	—	—	—
Fludarabine and Prednisone Variant #01	—	R 14 039	28d	—	—	—	—	—
FCM Variant #01	—	R 13 494	28d	—	—	—	—	—
miniCHOP-F Variant #01	—	R 12 440	30d	—	—	—	—	—
Fludarabine monotherapy Variant #01	—	R 11 691	28d	23.3 mo	52.9 mo	26	R 303 962 PFS proxy	2
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	30.8 mo	—	11	R 69 973 PFS proxy	1
Chlorambucil monotherapy Variant #12	—	R 2 523	14d	12.6 mo	—	28	R 70 639 PFS proxy	5
Chlorambucil and Prednisone Variant #01	—	R 1 275	30d	—	—	—	—	—
CHOP Variant #13	—	R 859	21d	~15.5 mo	—	~23	~R 19 749 PFS proxy · indirect	4
CAP Variant #01	—	R 671	30d	—	—	—	—	—
CVP Variant #01	—	R 585	21d	—	—	—	—	—
Uracil mustard monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—

17 of 17 regimens shown